Short Interest in Marker Therapeutics, Inc. (NASDAQ:MRKR) Expands By 62.7%

Marker Therapeutics, Inc. (NASDAQ:MRKR) was the target of a significant increase in short interest in May. As of May 15th, there was short interest totaling 244,966 shares, an increase of 62.7% from the April 30th total of 150,562 shares. Approximately 1.6% of the company’s shares are sold short. Based on an average trading volume of 64,788 shares, the short-interest ratio is presently 3.8 days.

Marker Therapeutics Trading Up 1.7%

Marker Therapeutics stock traded up $0.03 on Thursday, hitting $1.48. 32,124 shares of the stock traded hands, compared to its average volume of 214,022. The firm has a market cap of $24.59 million, a P/E ratio of -2.42 and a beta of 1.44. The business’s fifty day simple moving average is $1.46 and its 200 day simple moving average is $1.48. Marker Therapeutics has a 1 year low of $0.81 and a 1 year high of $4.07.

Marker Therapeutics (NASDAQ:MRKR) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.16) EPS for the quarter, beating the consensus estimate of ($0.18) by $0.02. The business had revenue of $0.75 million during the quarter, compared to analyst estimates of $0.78 million. Marker Therapeutics had a negative return on equity of 73.29% and a negative net margin of 343.03%. As a group, analysts predict that Marker Therapeutics will post -1.17 earnings per share for the current year.

Hedge Funds Weigh In On Marker Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC lifted its position in Marker Therapeutics by 41.8% during the first quarter. Renaissance Technologies LLC now owns 175,294 shares of the company’s stock valued at $228,000 after buying an additional 51,644 shares during the period. NewEdge Advisors LLC purchased a new position in shares of Marker Therapeutics in the 4th quarter worth about $222,000. XTX Topco Ltd raised its position in shares of Marker Therapeutics by 166.6% in the 4th quarter. XTX Topco Ltd now owns 58,041 shares of the company’s stock worth $86,000 after purchasing an additional 36,269 shares during the last quarter. Osaic Holdings Inc. raised its position in shares of Marker Therapeutics by 16.5% in the 4th quarter. Osaic Holdings Inc. now owns 94,421 shares of the company’s stock worth $141,000 after purchasing an additional 13,340 shares during the last quarter. Finally, Jane Street Group LLC purchased a new position in shares of Marker Therapeutics in the 4th quarter worth about $60,000. Hedge funds and other institutional investors own 22.39% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on the stock. HC Wainwright reiterated a “buy” rating on shares of Marker Therapeutics in a report on Wednesday, May 20th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Marker Therapeutics in a report on Friday, March 27th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Marker Therapeutics presently has an average rating of “Hold” and a consensus target price of $10.00.

Marker Therapeutics Company Profile

Marker Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of personalized T-cell immunotherapies for cancer. The company’s proprietary Maestro™ platform is designed to isolate, expand and activate a patient’s own T-cells against multiple tumor-associated antigens simultaneously. By leveraging next-generation sequencing and advanced cell processing techniques, Marker aims to overcome tumor immune evasion and deliver targeted immune responses in solid tumors and hematologic malignancies.

Marker’s lead programs include autologous T-cell therapies engineered to recognize viral-associated and self-antigens that are overexpressed in certain cancers.